KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvqVZlKSzVyPUOuNlc{PTJizszN MkPHV2FPT0WU
HuO-3N1 M{Lpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW1OWVKSzVyPUSuNVcyPDJizszN NVnSWYF1W0GQR1XS
LAMA-84 M4jKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF32RZFKSzVyPUSuOVg1PjVizszN MorxV2FPT0WU
CAL-72 M3fFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID6bmdKSzVyPUWuOFgxQDRizszN NF7hT|RUSU6JRWK=
LoVo MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13LO2lEPTB;Nj65N|I{QSEQvF2= NY\ldWtoW0GQR1XS
HH MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\QTWM2OD16LkK3OlcyKM7:TR?= M2jrTHNCVkeHUh?=
SK-MEL-3 NXyyZ2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXhWZNZUUN3ME24MlI5PTd3IN88US=> MV\TRW5ITVJ?
KM12 NXLSUnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTlwMkGxOFIh|ryP MnK1V2FPT0WU
NCI-H1437 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iXVdTUUN3ME25MlgxQTdizszN Ml7zV2FPT0WU
NCI-H1838 NYPlTYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqwUlZLUUN3ME2xNU4yQDZ3IN88US=> MUPTRW5ITVJ?
J-RT3-T3-5 NFTvSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jFVWlEPTB;MUGuNlQyPyEQvF2= MlrLV2FPT0WU
GOTO MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLuTWM2OD1zMT62PVk3KM7:TR?= M{\s[nNCVkeHUh?=
LB2241-RCC Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHZTWM2OD1zMT63NVg3KM7:TR?= NUjlcHB[W0GQR1XS
ES7 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFzLke4PEDPxE1? NH7LR3hUSU6JRWK=
KP-N-YS NF32[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1zMj62N|U1KM7:TR?= M{W3XnNCVkeHUh?=
CAL-12T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsV2lEPTB;MUOuOlE4KM7:TR?= M{\DOnNCVkeHUh?=
COLO-684 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhUllKSzVyPUG0MlE2PjlizszN M3vRc3NCVkeHUh?=
DOK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZ[m9KSzVyPUG1MlM{OjlizszN NFf4RnRUSU6JRWK=
Hs-578-T Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HTWM2OD1zNT60NVgzKM7:TR?= MYLTRW5ITVJ?
D-423MG NEC1UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF3LkWyN|Yh|ryP NEXwS|NUSU6JRWK=
DBTRG-05MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTITWM2OD1zNT62NVEyKM7:TR?= MUDTRW5ITVJ?
VM-CUB-1 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULkSIdZUUN3ME2xOU46QDR7IN88US=> MlXBV2FPT0WU
KG-1 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHDW5BKUUN3ME2xOk4xQTl4IN88US=> MmHtV2FPT0WU
8305C MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXeldKSzVyPUG2MlE5QDlizszN MmTzV2FPT0WU
HuH-7 M13PUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrHZ|BKSzVyPUG2MlI3PzRizszN MWLTRW5ITVJ?
LXF-289 M4KwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e4fWlEPTB;MU[uNlc1PyEQvF2= M1roVHNCVkeHUh?=
NCI-H1793 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF4LkS3NVIh|ryP MlToV2FPT0WU
ChaGo-K-1 M2ToRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rXNmlEPTB;MU[uOlU3QCEQvF2= MVPTRW5ITVJ?
GCIY NYKxRWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvHRoJKSzVyPUG2Mlc6ODVizszN MnqyV2FPT0WU
SK-MEL-28 NUXjNlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\FTWM2OD1zNz6wOFc2KM7:TR?= MVrTRW5ITVJ?
NCI-SNU-1 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL6[nVkUUN3ME2xO{4yOjZ7IN88US=> NFnzcIxUSU6JRWK=
CTB-1 M2DM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF5LkKyOVkh|ryP M2\HcHNCVkeHUh?=
NCI-H82 M3\NdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX74VpVXUUN3ME2xO{41PTd|IN88US=> MXrTRW5ITVJ?
HCC2998 M3;OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfSPJBKSzVyPUG3MlY4OzNizszN MXHTRW5ITVJ?
NCI-H2030 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF6LkG5PVch|ryP M1zLNXNCVkeHUh?=
HuP-T3 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF6LkW4PFgh|ryP NY\RRXU5W0GQR1XS
697 NXvMcXpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH2R5NQUUN3ME2xPU4xOjBzIN88US=> MX3TRW5ITVJ?
MLMA NIHtXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF7LkC1OVch|ryP NEHBS21USU6JRWK=
HCC70 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7xdXZKSzVyPUG5MlQ5QSEQvF2= NX:4V4FTW0GQR1XS
A704 NHLRfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[zZmlEPTB;MUmuPFMxPSEQvF2= NYjQfpdRW0GQR1XS
D-283MED Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3zRYlKSzVyPUKwMlU{OzlizszN MoPpV2FPT0WU
U031 M3HZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjpe49KSzVyPUKxMlE1QDlizszN NETG[GdUSU6JRWK=
HSC-3 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLCSnVQUUN3ME2yNU4yQDN3IN88US=> NHPxfJFUSU6JRWK=
JVM-3 NITZWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i5RmlEPTB;MkKuOVA3KM7:TR?= NFW5UWlUSU6JRWK=
Mewo M1qwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHGV4dvUUN3ME2yNk42ODd|IN88US=> MnrFV2FPT0WU
YH-13 NYHjO2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjITWM2OD1{Mj61NVI{KM7:TR?= MnnXV2FPT0WU
LB1047-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPRW9sUUN3ME2yNk42QDd7IN88US=> MVzTRW5ITVJ?
HCC2157 NW\MXlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ{LkiwOVQh|ryP NV3MPYVLW0GQR1XS
SNU-449 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3pTWM2OD1{Mj64O|Q5KM7:TR?= NWr1S4RPW0GQR1XS
Ramos-2G6-4C10 NHzFTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3FTWM2OD1{Mj65OkDPxE1? M3LGXnNCVkeHUh?=
CHL-1 M{Pj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5fVVKSzVyPUKzMlczQTJizszN NXmzfZRxW0GQR1XS
SK-MEL-30 M4PJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzbmdKSzVyPUK0MlQ3PjJizszN MkfhV2FPT0WU
PANC-08-13 NITvUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHlTWM2OD1{NT6wPVM5KM7:TR?= M1fBVXNCVkeHUh?=
QIMR-WIL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ3LkG4OVgh|ryP NYn0ZZY5W0GQR1XS
BFTC-905 M3TMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLmTWM2OD1{NT61PVQ1KM7:TR?= MkjRV2FPT0WU
GI-1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\DTWM2OD1{NT63NFU2KM7:TR?= MoCxV2FPT0WU
MDA-MB-415 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLsRYU2UUN3ME2yOk42ODN|IN88US=> MnjTV2FPT0WU
GT3TKB Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;PTWM2OD1{Nj61N|QzKM7:TR?= MVHTRW5ITVJ?
DEL NWnhe|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHPTnJ{UUN3ME2yOk45OzV4IN88US=> NV7RS3F6W0GQR1XS
KOSC-2 NVTsXZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\oNmlEPTB;Mk[uPVA4PSEQvF2= NYGwR3Q5W0GQR1XS
RVH-421 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXQTWM2OD1{Nz6yPVIyKM7:TR?= M{fHV3NCVkeHUh?=
EW-13 NYPkNoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\p[GlEPTB;MkeuOFMxQCEQvF2= MXLTRW5ITVJ?
639-V MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ5LkWxNVkh|ryP MlTlV2FPT0WU
A2780 MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37STmlEPTB;MkeuOlQyKM7:TR?= NULCSXNkW0GQR1XS
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZWmlEPTB;MkeuPVA2OiEQvF2= MkfHV2FPT0WU
SW1710 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;wW5NoUUN3ME2yPE4xQThzIN88US=> MkXXV2FPT0WU
HCC1569 NXztfYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT1ZXVEUUN3ME2yPE41QDl5IN88US=> MXjTRW5ITVJ?
MV-4-11 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ6LkW3N|Uh|ryP NF7UXIJUSU6JRWK=
BHT-101 NIfnTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnFXWdrUUN3ME2yPE43PTd{IN88US=> NIL1bWNUSU6JRWK=
Ca9-22 NXrjTFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjM[ZNCUUN3ME2yPE44OTRizszN Mmn3V2FPT0WU
HAL-01 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ6Lke2NVUh|ryP NIe1eZFUSU6JRWK=
D-263MG NFLUW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TGfGlEPTB;MkmuN|Q1KM7:TR?= MUHTRW5ITVJ?
NEC8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[3R5BxUUN3ME2yPU42PTR6IN88US=> MVfTRW5ITVJ?
EKVX MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNzLkW4OFch|ryP MYrTRW5ITVJ?
EM-2 NXH2OoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvoU3RYUUN3ME2zNU43OzB2IN88US=> Ml\oV2FPT0WU
MFM-223 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNzLkiwPVgh|ryP MknPV2FPT0WU
SK-PN-DW NUW4RVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36zRWlEPTB;M{KuNVQxPiEQvF2= M3X5fnNCVkeHUh?=
HuO9 NF\kNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN{LkWyPFIh|ryP NF3TVJlUSU6JRWK=
MHH-PREB-1 NXvUcHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHPZoU4UUN3ME2zNk43OjN2IN88US=> MYnTRW5ITVJ?
OVCAR-4 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f2b2lEPTB;M{KuPFM3OyEQvF2= NHOyWZVUSU6JRWK=
NCI-H1648 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN{Lki2OVEh|ryP MX3TRW5ITVJ?
MKN1 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj4NGxUUUN3ME2zOE4yOTBzIN88US=> Ml[0V2FPT0WU
KYSE-450 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PwWGlEPTB;M{SuOlQ1PCEQvF2= Mn;sV2FPT0WU
ES8 M1PP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGfmlEPTB;M{SuPFk4PSEQvF2= MUXTRW5ITVJ?
MS-1 NVfTZ4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN2Lkm1OVQh|ryP NFXXd5lUSU6JRWK=
HOP-92 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN3LkmyO|ch|ryP M3HoOHNCVkeHUh?=
SKG-IIIa M3v0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN4LkK1OlEh|ryP NH\XeJBUSU6JRWK=
TE-11 M1ywUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnUTWM2OD1|Nj61NlQ{KM7:TR?= MY\TRW5ITVJ?
SK-NEP-1 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C0NWlEPTB;M{euOlc1PCEQvF2= NUXEOXV7W0GQR1XS
DB M3r3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4[2lEPTB;M{euPVE5PSEQvF2= M3jSbXNCVkeHUh?=
IA-LM NUewUJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN6LkCyN|kh|ryP MknqV2FPT0WU
COLO-829 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD1|OD60NVU6KM7:TR?= MXnTRW5ITVJ?
TGBC11TKB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD1|OT6xOFA5KM7:TR?= M2j2OXNCVkeHUh?=
CAL-51 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDWHBKSzVyPUSwMlA3OTJizszN MXPTRW5ITVJ?
NCI-H2228 NEDxfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRyLkO2OlIh|ryP MmTSV2FPT0WU
C32 NGHvS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRyLkSwNlQh|ryP NHO1NGtUSU6JRWK=
KU-19-19 NHqz[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD12MD63Olg{KM7:TR?= Mk\TV2FPT0WU
KNS-62 NEPwdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jNS2lEPTB;NECuPFM5OSEQvF2= NFv4VlhUSU6JRWK=
FADU NF\BcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPtTWM2OD12MT6yOVAzKM7:TR?= MYPTRW5ITVJ?
CAL-33 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\tZmZVUUN3ME20Nk43PzR7IN88US=> NHrad25USU6JRWK=
CHP-134 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmze3ZKSzVyPUSyMlg1QTZizszN MoT1V2FPT0WU
HDLM-2 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILE[lBKSzVyPUSyMlkxQDRizszN MULTRW5ITVJ?
NBsusSR NIXzXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfkTWM2OD12Mz6wO|I2KM7:TR?= M3fTVHNCVkeHUh?=
SW954 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjoVpJKSzVyPUSzMlExPTNizszN NVzNPFJsW0GQR1XS
HCC1806 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvMTWM2OD12Mz60NVEh|ryP NFT6XWNUSU6JRWK=
VMRC-RCZ NWPkbXdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PZZmlEPTB;NEOuOFU5PiEQvF2= NVvUTll5W0GQR1XS
A549 M1;n[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\xTWM2OD12Mz65N|Eh|ryP NI\GdWVUSU6JRWK=
NKM-1 M3fJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH3NI1wUUN3ME20N{46PTV6IN88US=> NIjhcnFUSU6JRWK=
DMS-273 NICyOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Mc2RKSzVyPUS0Mlc2PjdizszN MWXTRW5ITVJ?
TYK-nu NXnBW4NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LyW2lEPTB;NEWuNVI{PCEQvF2= MXHTRW5ITVJ?
KALS-1 M3zWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTyNFNKSzVyPUS1MlE1PiEQvF2= NE\3dJdUSU6JRWK=
A101D NVfZ[phCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zTb2lEPTB;NEWuOFQ2PiEQvF2= NWDmSYVwW0GQR1XS
G-361 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnyWFRqUUN3ME20Ok4zOTN6IN88US=> MYfTRW5ITVJ?
KARPAS-299 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmd2lEPTB;NE[uN|UyPiEQvF2= NVLOd4NwW0GQR1XS
RS4-11 NVjLeYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\tTWM2OD12Nj61OFIh|ryP NXrwSXpzW0GQR1XS
HT-1376 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR4Lke0NlYh|ryP NEPT[YRUSU6JRWK=
SK-N-AS NGHGTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrPeXNyUUN3ME20Ok44QDJ{IN88US=> M{jWO3NCVkeHUh?=
MG-63 NFKyPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR4LkmwN|Yh|ryP NF:1fJpUSU6JRWK=
EPLC-272H NGXi[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXx[XFmUUN3ME20Ok46PTB|IN88US=> MkLYV2FPT0WU
BALL-1 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHINpd1UUN3ME20O{45OzJizszN NXrlfHYxW0GQR1XS
LCLC-97TM1 NYfLd|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nXO2lEPTB;NEiuNlAzKM7:TR?= NYfQdW0yW0GQR1XS
HO-1-N-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR6Lkm2O|Yh|ryP MlTOV2FPT0WU
MFE-280 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnsUndUUUN3ME20PU41PjF5IN88US=> NH7ae3dUSU6JRWK=
NCI-H526 NV;zVXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NXWNKSzVyPUS5MlgyPjNizszN MVvTRW5ITVJ?
D-566MG MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ht[2lEPTB;NEmuPVA6PiEQvF2= M4W2O3NCVkeHUh?=
BB30-HNC NHX4XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHrSlFKSzVyPUS5Mlk1QThizszN NW\lTJd[W0GQR1XS
SK-N-DZ NYTMdGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIiwOI9KSzVyPUWwMlA1QDFizszN MmnhV2FPT0WU
HepG2  NW\aUG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;DNVExyqEQvF2= NVe2OJl6OjRiaB?= NID4UY5jdG:la4OgV2MuUUmLMz3pcoR2[2WmIGOgdIhie2ViYYLy[ZN1 MUOyOVUzPzF{Mx?=
HepG2  MYXGeY5kfGmxbjDBd5NigQ>? MnvlNVDDqM7:TR?= Mo\KNlQhcA>? Mle5d5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> MYWyOVUzPzF{Mx?=
KATO III  NWL1b3diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme0Nk42NzVxNz61JO69VQ>? NUS0N4tOTE2VTx?= M2PnboVvcGGwY3XzJJRp\SC2b4jpZ4l1gSCxZjDvcIFx[XKrYh?= MWqyOFg1OTdzOB?=
hTCEpi MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmxNEDPxE1? M1vYfGROW09? M3W1O5Bz\X[nboTzJJRp\SCleYTvdIF1cGmlIHXm[oVkfCCxZjDIV3YuOQ>? M{\XWFI1OzdyOEO1
MCF10A NY\0cmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjxdFAyOCEQvF2= M4D6V|I1KGh? MlP1SG1UVw>? MVvwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD M2rSVlI1OTVyNUm1
HL-60  NUToOXhmTnWwY4Tpc44hSXO|YYm= NYDtNIExOTBizszN MWOwMlUhcA>? M3iyR2ROW09? NFPFUo1z\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC= Mk\RNlM6OzR2MUG=
MCF-7 NI[0S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxMVExOM7:TR?= MnO4NlQhcA>? MXXGRnM> MVTpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v M1frfFI{OTh3M{S3
HeLa  NFftc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\JRVEuOTByzszN M3LsWlI1KGh? MoTFSmJU Mnu5bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MYCyN|E5PTN2Nx?=
SH-SY5Y M1jtR2Z2dmO2aX;uJGF{e2G7 M3H5OFExyqEQvF5CpC=> NWGwepV5OjRiaB?= NWDQdGxtcW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= NVXOcJlDOjJ4MkeyPVQ>
IMR-32 NFnkPW9HfW6ldHnvckBCe3OjeR?= M3XYbVExyqEQvF5CpC=> NYHvb25[OjRiaB?= NEDkdmFqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= NXPtSXU3OjJ4MkeyPVQ>
A549 MoDNSpVv[3Srb36gRZN{[Xl? MUGxNOKh|ryPwrC= M4XKflEhcA>? MVjzeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w Ml\VNlI2PTl|MkG=
T47D  NFzzU3VHfW6ldHnvckBCe3OjeR?= MWKyNOKhdU1? NWfoOVdoOjRiaB?= NFv6VndFVVOR NGL4S3RxemW4ZX70d{BKWi2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJGnPwkMQsR?= NFj2eZczOTF2NEiwOS=>
A29 MEF MV7GeY5kfGmxbjDBd5NigQ>? NFTXd4MyOMLizszNxsA> MXKxbC=> MnfwZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> NFfSUmEzODB3M{e4NS=>
MDA-MB-453  MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTLT5U2NTRyIN88US=> MnvmO|IhcA>? M{fQOWlEPTBib3[gNVAh|ryP NI\TNmwzODB3M{e4NS=>
PC-3 NVnKWJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vmT|UuPDBizszN NX:0Vo9rPzJiaB?= MYjJR|UxKG:oIEGwJO69VQ>? M3K1fVIxODV|N{ix

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products4

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID